Journal of Hepatology
Volume 52, Issue 5 , Pages 672-680 , May 2010

Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation

  • Takasuke Fukuhara

      Affiliations

    • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 92 642 5466; fax: +81 92 642 5482.
    • ,
  • Akinobu Taketomi

      Affiliations

    • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
    • ,
  • Shinji Okano

      Affiliations

    • Division of Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    • ,
  • Toru Ikegami

      Affiliations

    • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
    • ,
  • Yuji Soejima

      Affiliations

    • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
    • ,
  • Ken Shirabe

      Affiliations

    • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
    • ,
  • Yoshihiko Maehara

      Affiliations

    • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Received 21 June 2009 ,Revised 2 September 2009 ,Accepted 7 October 2009.

References 

  1. Manns MP, Mchutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  2. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44:97–101
  3. Brown RS. Hepatitis C and liver transplantation. Nature. 2005;436:973–978
  4. Marubashi S, Dono K, Miyamoto A, Takeda Y, Nagano H, Umeshita K, et al. Liver transplantation for hepatitis C. J Hepatobiliary Pancreat Surg. 2006;13:382–392
  5. Neumann UP, Berg T, Bahra M, Puhl G, Gucklberger O, Langrehr JN, et al. Long-term outcome of liver transplantation for chronic hepatitis C: a 10-year follow-up. Transplantation. 2004;77:226–231
  6. Mazzaferro V, Regalla E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699
  7. Freeman RB. Transplantation for hepatocellular carcinoma: the Milan criteria and beyond. Liver Transpl. 2006;12:8–13
  8. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830–836
  9. Veldt BJ, Poterucha JJ, Watt KDS, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transpl. 2008;8:2426–2433
  10. Berardi S, Lodato F, Gramenzi A, D’Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis. Gut. 2007;56:237–242
  11. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290:228–237
  12. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2007;79:1686–1695
  13. Enomoto N, Sakura I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77–81
  14. El-Shammy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination threrapy. Hepatology. 2008;48:38–47
  15. Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Harada N, Ijichi H, et al. Feasibility of left lobe living donor liver transplantation between adults: an 8-year, single-center experience of 107 cases. Am J Transpl. 2006;6:1004–1011
  16. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology. 1997;25:750–753
  17. Sarrazin C, Berg T, Lee JH, Teuber G, Dietrich CF, Roth WK, et al. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C type 1b undergoing combination therapy. J Hepatol. 1999;30:1004–1013
  18. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 1997;230:217–227
  19. Noguchi T, Satoh S, Noshi T, Hatada E, Fukuda R, Kawai A, et al. Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells. Microbiol Immunol. 2001;45:829–840
  20. Lyra AC, Fan X, Lang DM, Yusim K, Ramrakhiani S, Brunt EM, et al. Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology. 2002;123:1485–1493
  21. Schvoerer E, Soulier E, Royer C, Renaudin AC, Thumann C, Fafi-Kremer S, et al. Early evolution of hepatitis C virus (HCV) quasispecies after liver transplant for HCV-related disease. J Infect Dis. 2007;196:528–536
  22. Feliu A, Carrion JA, Massaguer A, Martinez-bauer E, Garcia-Retortillo M, Gonzalez P, et al. Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. J Viral Hepat. 2006;13:544–551
  23. Berenguer M. Systemic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274–287
  24. Oton E, Barcena R, Moreno-Planas JM, Cuevas-Mons V, Moreno-Zamora A, Barrios C, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin. Am J Transpl. 2006;6:2348–2355
  25. Picciotto FP, Tritto G, Lanza AG, Addario L, Luca MD, DiCostanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007;46:459–465
  26. Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl. 2007;13:1100–1108
  27. Weston SJ, Leistikow RL, Reddy KR, Torres M, Wertheimer AM, Lewinsohn DM, et al. Reconstruction of hepatitis C virus-specific T-cell-mediated immunity after liver transplantation. Hepatology. 2005;41:72–81
  28. Su X, Yee LJ, Im KA, Rhodes SL, Tang YM, Tong X, et al. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol. 2008;49:184–191
  29. Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transpl. 2006;6:449–458

PII: S0168-8278(10)00080-2

doi: 10.1016/j.jhep.2009.10.034

Journal of Hepatology
Volume 52, Issue 5 , Pages 672-680 , May 2010

Article Tools

* Image Usage & Resolution